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OBJECTIVES We report histological analysis of hearts from patients with end-stage heart disease who were
transplanted with autologous skeletal myoblasts concurrent with left ventricular assist device
(LVAD) implantation.
BACKGROUND Autologous skeletal myoblast transplantation is under investigation as a means to repair
infarcted myocardium. To date, there is only indirect evidence to suggest survival of skeletal
muscle in humans.
METHODS Five patients (all male; median age 60 years) with ischemic cardiomyopathy, refractory heart
failure, and listed for heart transplantation underwent muscle biopsy from the quadriceps
muscle. The muscle specimen was shipped to a cell isolation facility where myoblasts were
isolated and grown. Patients received a transplant of 300 million cells concomitant with
LVAD implantation. Four patients underwent LVAD explant after 68, 91, 141, and 191 days
of LVAD support (three transplant, one LVAD death), respectively. One patient remains
alive on LVAD support awaiting heart transplantation.
RESULTS Skeletal muscle cell survival and differentiation into mature myofibers were directly demon-
strated in scarred myocardium from three of the four explanted hearts using an antibody
against skeletal muscle-specific myosin heavy chain. An increase in small vessel formation was
observed in one of three patients at the site of surviving myotubes, but not in adjacent tissue
devoid of engrafted cells.
CONCLUSIONS These findings represent demonstration of autologous myoblast cell survival in human heart.
The implanted skeletal myoblasts formed viable grafts in heavily scarred human myocardial
tissue. These results establish the feasibility of myoblast transplants for myocardial repair in
humans. (J Am Coll Cardiol 2003;41:879–88) © 2003 by the American College of
Cardiology Foundation
Cell transplantation represents a novel therapeutic approach
for the treatment of end-stage heart disease. Accumulating
evidence from a number of studies suggests that myocardial
function can improve after cell transplantation (1–8). Ex-
perimental studies have explored the use of a number of
different cell types that include embryonic stem cells (9),
cardiac myocytes (10), fetal or neonatal cardiomyocytes
(11–15), skeletal myoblasts (7,16–21), fibroblasts (17), and
hematopoietic stem cells (1–3,5,6,22). Skeletal muscle, be-
cause of its capacity to regenerate, has become an increas-
ingly used source of cells for cardiac repair. Skeletal myo-
blasts are readily obtained by routine muscle biopsy, and
autografts can be utilized to avoid the risk of graft rejection.
Injection of skeletal myoblasts in animal models of heart
failure improves cardiac performance and, in most cases, is
accompanied by histologic demonstration of graft survival
(7,16–18,23–25). Recently, skeletal muscle cell transplan-
tation has been performed in humans undergoing coronary
artery bypass grafting for ischemic heart failure (26). How-
ever, to date, evidence for cell survival in humans is based on
indirect measures of improvements in global or regional
myocardial function (4). Further, because skeletal myoblast
implantation studies in humans were performed in conjunc-
tion with coronary revascularization, the functional benefits
attributed solely to skeletal myoblast implantation and
hence, cell survival, become difficult to interpret in this
experimental model. No histological evidence of skeletal
myoblast survival in human heart, nor efficiency of cellular
engraftment, exists for humans. For the appropriate feasi-
bility of cardiac repair by cell transplants to be proven in
humans, histologic confirmation of transplant survival and
differentiation is essential.
We undertook a phase I clinical study to investigate the
feasibility and safety of autologous skeletal muscle cell
transplants in human patients with ischemic heart disease
undergoing left ventricular assist device (LVAD) implanta-
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tion as a bridge to orthotopic heart transplantation. With
this protocol, the viability of cell transplants can be evalu-
ated histologically in recipient hearts after heart transplant.
METHODS
The phase I clinical study was approved by the Institutional
Review Board for Human Studies (University of Michigan)
and was conducted in accordance with federal guidelines
under an approved investigational new drug and informed
consent process. A total of 24 patients were screened for the
trial. Ten patients were consented and underwent muscle
biopsy. Five patients underwent LVAD implantation con-
current with myoblast transplantation. Five of 10 patients
required urgent LVAD implantation before culturing suf-
ficient numbers of myoblasts for injection.
Study subjects and protocol. All patients (n  5) under-
going LVAD implantation concurrent with myoblast trans-
plantation were male, with a median age of 60 years and a
history of ischemic cardiomyopathy (Table 1). All were
listed for heart transplantation at the time of LVAD
implantation. All had a previous sternotomy for coronary
artery bypass grafting. Median left ventricular ejection
fraction was 15%. All patients were inotrope-dependent at
the time of LVAD implantation. Median values for heart
rate, systemic blood pressure, cardiac index, pulmonary
capillary wedge pressure, and mean pulmonary artery pres-
sure at the time of LVAD implantation were 83 beats/min,
76 mm Hg, 2.8 l/m2/min, 18 mm Hg, and 33 mm Hg,
respectively.
Muscle biopsies were taken from the right quadriceps
muscle under sterile conditions using local anesthetics. The
muscle specimens were immediately placed in transport
medium and sent to a GMP isolation facility. Approxi-
mately four weeks after muscle biopsy (n  4; 1 patient
underwent cell transplant at 13 days after biopsy because of
urgent need for LVAD implantation), all patients under-
went LVAD implantation concurrent with myoblast trans-
plantation. Multiple injections of autologous skeletal myo-
blasts were made into the anterior wall (n  4) or lateral
wall (n  1) of the left ventricle using a 0.5- (n  1) to
3-inch long (n  4) 25- or 26-gauge needle (Table 1).
Injection location was selected based upon echocardiogra-
phy before surgery, and direct visualization during the
surgical procedure. For all patients, 100-l injections were
delivered with a uniform spacing at a constant slow rate of
delivery. All of the injections were made into a designated
area within a myocardial infarct or border zone of the
infarct, approximately 3  3 cm2, and demarcated with
Abbreviations and Acronyms
EDTA  ethylenediaminetetraacetic acid
FACS  fluorescence activated cell sorting
LVAD  left ventricular assist device
mAb  monoclonal antibody
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surgical clips. All injections were made before the initiation
of cardiopulmonary bypass. The LVAD implant procedure
was completed in the usual fashion.
After 68, 91, 144, and 191 days of LVAD support, four
patients underwent LVAD explantation (three heart trans-
plant, one LVAD death). At the time of LVAD explant,
the portion of the left ventricle demarcated by the surgical
clips was excised and fixed in formalin solution for histo-
logical analysis. Currently, one patient remains alive and
well on LVAD support awaiting heart transplantation. The
three patients surviving to heart transplantation remain alive
and well at 1, 6, and 10 months, respectively.
Preparation of the autologous skeletal myoblasts.
Approximately 2 g of skeletal muscle were obtained at each
biopsy and subsequently stripped of connective tissue, minced
into a slurry, and subjected to several cycles of enzymatic
digestion at 37°C with trypsin/ethylenediaminetetraacetic acid
(EDTA) (0.5 mg/ml trypsin, 0.53 mM EDTA; Gibco-
BRL) and collagenase (0.5 mg/ml; GibcoBRL) to release
satellite cells. Skeletal myoblasts were cultured according to
a modified Ham’s method (27). Satellite cells were plated
and grown in myoblast basal growth medium (SkBM;
Clonetics) containing 15% to 20% fetal bovine serum
(Hyclone), recombinant human epidermal growth factor
Figure 1. Human skeletal myoblast expansion and purity. A shows the anti-CD56 staining profile of the final myoblast product implanted to Patient 2 using
flow cytometry. B (10) and C (4) show the myoblast cells in culture during expansion. D (10) and E (4) show the potential of these cells to fuse
and form multinucleated myotubes in an in vitro assay. Some of these multinucleated myotubes are highlighted with arrows in D.
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(10 ng/ml), and dexamethasone (3 g/ml). To avoid any
possibility of myotube formation during the culture process,
cell densities were maintained throughout the process so
that 75% of the culture surface was occupied by cells. All
cells were expanded for 11 to 12 doublings and were
cryopreserved before transplant. After thaw, myoblasts (as
single-cell suspension) were washed and suspended in trans-
plantation medium at approximately 80 million cells per cc,
loaded into five 1-cc tuberculin syringes, chilled to 4°C, and
shipped on ice to the clinical center for transplant. At the
time of transplant, cells were warmed to room temperature
and injected without further manipulation. Viabilities for
the cell suspension at the time of transplant were 90%
(Table 1).
Myoblast purity was measured by reactivity with anti-
CD-56 monoclonal antibody (mAb) (5.1H11, supplied by
Dr. Robert Brown) using fluorescence-activated cell sorting
(FACS). This antibody selectively stains human myoblasts
and not fibroblasts (28). The percent myoblasts ranged from
43% to 97% (Table 1, Fig. 1). The ability of myoblasts to
fuse into multinucleated myotubes in vitro was also con-
firmed by seeding 2  105 cells per 24-well tissue culture
plate in growth medium. The following day, the culture
medium was switched to fusion medium (Dulbecco’s min-
imal essential medium with 0.1% bovine serum albumin and
50 ng/ml insulin-like growth factor), and cultures were
observed three days later to assess fusion. Fusion was only
used to confirm the presence of myoblasts. Cells were not
fused before transplant. Sterility tests were conducted on the
final product as well as throughout the digestion and
expansion procedures.
Histological analysis and immunohistochemical tech-
niques. Excised myocardium was fixed in formalin, cut into
2  3 cm blocks, and paraffin-embedded; 5  thick sections
were cut, mounted, and stained with trichrome. For detec-
tion of skeletal muscle, deparaffinized sections were incu-
bated with alkaline phosphatase-conjugated MY-32 mAb
(Sigma-Aldrich, Inc., St. Louis, Missouri), a skeletal muscle
reactive anti-myosin heavy chain antibody that does not
stain cardiac muscle (29). Sections were developed with
BCIP-NBT (Zymed Lab Inc.) and counterstained with
nuclear red. Detection of slow-twitch myosin isoforms was
performed with an antibody directed against myosin heavy
chain beta (Clone NOQ7.5.4D, Chemicon, Temecula,
California). For detection of vascular endothelial cells,
sections were stained with anti-CD-31 mAb (Clone JC/
70A, DAKO Corp., Carpenteria, California) and T cells
with polyclonal rabbit anti-human CD3 reagent (DAKO).
Figure 2. Representative trichrome and MY-32 stain of grafted skeletal myoblasts. A shows an area of the graft in a section stained with trichrome. B shows
an adjacent section that was stained with the skeletal myosin specific MY-32 antibody. The transplant derived myofibers can be identified by the red staining
in trichrome and the dark blue staining in the MY-32 stain. Asterisks (*) mark areas of host myocardial fibers. Scale bar  50 m.
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Deparaffinized sections were stained and developed accord-
ing to the manufacturer’s recommendations. Incubation
with secondary antibodies was performed according to
instructions for Vectastain Mouse Elite or Vectastain Goat
Elite Horse Radish Peroxidase conjugates (Vector Labora-
tories, Burlingame, California). Sections were developed
with diaminobenzidine (DAB Substrate Kit; Vector Labo-
ratories) and counterstained with hematoxylin.
For vascular endothelium quantitation, a total of six
independent locations within the implanted regions were
immunostained with anti-CD-31 mAb. Counts were per-
formed in the region of the grafted cells and in the
non-transplanted scar region immediately adjacent to the
graft. Each field was photographed using an Olympus
microscope with a 20 objective and a Kodak digital
camera. The image was then acquired in Photoshop 5.0, and
the entire field was counted for individual vascular elements.
Counts were analyzed and statistical analysis performed by
a Student t test for paired data. Statistical significance was
defined at p  0.05.
RESULTS
Skeletal myoblasts were expanded 11 to 13 population
doublings in culture with an average doubling time of 29 h.
Before transplantation, the population of cells contained
only single cells and no fused multinucleated myoblasts. The
myoblast purity of cell preparations varied between 43% and
97%, based on skeletal muscle-specific anti-CD-56 mAb
staining and FACS analysis, with the remainder of the cells
being composed of fibroblasts (Table 1, Fig. 1). The final
myoblast preparation was characterized further by demon-
strating the capacity to fuse and form multinucleated myo-
tubes (Fig. 1).
Approximately 300  106 cells were transplanted using
multiple injections into the left ventricular wall of each
patient. The dose of cells was selected to provide sufficient
histological evidence to demonstrate graft survival. We did
not investigate for changes in regional function in this
protocol. At the time of orthotopic heart transplantation,
the explanted heart was fixed and sectioned. Surviving
autologous skeletal muscle cells were identified in scarred
tissue of the heart by trichrome staining in all patients
except Patient 1 (Figs. 2 to 4). Patient 1 underwent injection
with a suboptimal number of cells due to the urgent need for
LVAD. Myofiber structures were identified within the
transplanted region by the red trichrome stain characteristic
of cardiac and skeletal muscle as opposed to the blue stain
associated with fibroblasts and collagen of the scar (Figs.
2A, 3A, 3B, 4A, and 4B). Myofibers continued throughout
several blocks of tissue spanning an area of approximately
1.2 cm in length and 2 cm in width for Patients 2 and 3,
whereas in Patient 5, cells were present over the entire 3 
3 cm target area. The red-stained myofiber tissue was
confirmed to be of skeletal origin by staining for skeletal
muscle-specific myosin heavy chain (Figs. 2B, 3C, and 4C).
Figure 3. Representative trichrome and MY-32 stain of grafted skeletal
myoblasts. A and B show an area of the graft in a section stained with
trichrome at two magnifications. In A, the myotubes can be clearly
identified, and in B the higher magnification shows the presence of striated
myofibers in some myotubes. C shows an adjacent section that was stained
with the skeletal myosin specific MY-32 antibody.
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Only the transplanted skeletal muscle fibers stain for
muscle-specific myosin heavy chain and not the host cardiac
muscle fibers. Additionally, most of the transplant-
associated myofibers were aligned in parallel with the host
myocardial fibers (Figs. 2 and 4). No differences in mor-
phology or survival of transplanted cells were noted between
implants within scarred myocardium or adjacent to healthy
myocardium (Figs. 2A, 2B, and 4). Additionally, slow-
twitch myosin isoforms were identified within surviving
skeletal myoblasts using an antibody directed against myosin
heavy chain beta (Fig. 4).
Total myoblast cell survival was calculated to be 1%
based on a delivered dose of 300 million cells for Patients 2
and 3 (see Discussion) and was not calculated for Patient 5.
Cell survival was estimated by assuming 100% delivery of
cells, performing cell counts on sequential serial sections
throughout the graft, and using the method of Abercrombie
to correct for double counting of cells (30).
To assess the presence of inflammatory cells associated
with autologous myoblast grafts, H&E staining was also
used. There was little or no evidence of lymphocyte infil-
tration associated with either grafted or non-grafted areas. This
conclusion was confirmed with T-cell specific anti-CD3 poly-
clonal antibody immunohistochemical staining (Fig. 5). There
were also examples of multinucleated giant cells detected in
and around the grafts, but not in non-grafted myocardium
(Fig. 6). The giant cells were seen in association with refractile
material likely introduced during injection of cells.
Immunohistochemical staining was also performed to
assess the presence of vascular endothelium in grafted and
non-grafted myocardium using an anti-CD-31 mAb (Fig.
7). Quantitative measurement from six independent graft
areas from a representative patient showed significantly
more CD-31 stained vessels at the sites of surviving grafts
(Figs. 7A and 7B) as compared with the number of vessels
in the corresponding non-grafted scar tissue (228  24 cells
per field in grafted area vs. 72  17 cells per field in
non-grafted area, respectively; p  0.0001) (Fig. 7B).
Figure 4. Skeletal fast and slow twitch myosin. Shown are surviving skeletal myofibers in the heart from Patient 5 stained with trichrome (A and B),
skeletal-specific fast myosin MY-32 (identification of fast twitch skeletal muscle myosin isoforms only) (C) and myosin heavy chain beta slow (D). A, C,
and D show adjacent sections from the same graft site, and B shows a different graft site from the same patient, but where the myofibers can be seen in
a longitudinal profile. Grafted skeletal myofibers have a distinct stain by trichrome that are marked by stars in B, and the alignment between grafted
myofibers and host myofibers is striking. The area of the graft is marked by the dotted line in A, C, and D and individual skeletal myofibers that stained
with slow myosin and not fast myosin (MY-32, C) are marked by arrowheads. All images were shot at the same magnification.
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ADVERSE EVENTS
No minor or major adverse events occurred related to the
cell transplant procedures or implant process. Major serious
adverse events reported included death secondary to sepsis
from a drive line site infection 68 days after LVAD
implantation (Patient 1); drive line site infection requiring
hospitalization for intravenous antibiotics (Patient 4); and
reoperation for bleeding on postoperative day 1 for coagu-
lopathy not related to the cell transplant injection site
(Patient 3). Four patients experienced cardiac arrhythmias.
Patients 2 and 4 experienced postoperative atrial fibrillation.
Patient 2 experienced ventricular tachycardia at the initia-
tion of cardiopulmonary bypass after a period of hypoten-
sion that required cardioversion. Patients 3 and 5 both
experienced brief episodes of ventricular tachycardia in the
immediate postoperative period that resolved with beta-
blockers and amiodarone therapy. All but one patient
(Patient 5) had a history significant for ventricular arrhyth-
mias. Preoperative history and holter monitoring docu-
mented nonsustained ventricular tachycardia (Patients 2, 3,
and 4), atrial fibrillation (Patient 4), and intraventricular
conduction delay (Patient 2). Patients 3 and 4 underwent
implantation of a cardiac defibrillator more than one year
before LVAD implantation. No clinically detected cerebro-
vascular events, strokes, or peripheral embolic events oc-
curred in any patient.
DISCUSSION
This study provides evidence for skeletal myoblast survival
and differentiation in human myocardium. Areas of surviv-
ing myoblasts were identified in trichrome-stained sections
and confirmed by use of the skeletal muscle-specific myosin
heavy chain antibody, MY-32. The dose of cells injected
was calculated based on animal studies to assess viability and
differentiation. This study was not designed to investigate
for regional improvements in myocardial function.
Animal models of myocardial infarction have demon-
strated the principle that skeletal myoblasts can be expanded
and transplanted into the heart (7,16–18,23–25). However,
human demonstration of myoblast transplantation has been
limited to one study that showed symptomatic improvement
with no direct evidence for cell survival (26). In that study,
myoblast transplantation was performed in conjunction with
coronary revascularization. Survival of transplanted cells was
inferred from improvements by positron emission tomog-
raphy in deoxyglucose metabolism and cardiac pumping
efficiency. Because of the revascularization performed, the
degree of functional improvement attributable solely to
myoblast implantation or estimates of the efficiency of
myoblast engraftment and differentiation cannot be deter-
mined.
We have previously shown that myosin heavy chain
staining is associated with rodent myoblast fusion and
myofiber formation (16). In that experimental study, myosin
heavy chain was not expressed in myoblasts early after
engraftment. However, with time, cells fused into myo-
tubes, differentiated into myofibers, and expressed myosin
heavy chain. We have not observed myosin heavy chain
staining before myoblast fusion and myofiber formation.
Thus, areas staining for myosin heavy chain within the
human grafts represent myoblasts that have survived trans-
Figure 5. Representative CD-3 staining of a graft site. The micrograph shows a graft site stained with an antibody to CD-3 to stain immune cells. Some
scattered macrophages can be identified in and around the graft site. Some of the macrophages can be seen in association with an area of the containing
giant cells. There is no collection of infiltrating immune cells at the graft site to indicate any ongoing immune reaction. The dotted line demarcates an
area of viable myocardium. The stars highlight the area with giant cells. Arrows mark the surviving transplanted muscle cells, and the arrowheads mark
the CD-3 positive macrophages.
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plantation and gone on to fuse and form myofibers as they
would in situ in skeletal muscle. Additionally, evidence of
skeletal myoblast differentiation with expression of slow-
twitch myosin isoforms was observed in surviving grafts. It
is noteworthy that the majority of myofibers surviving in the
human heart have aligned in parallel with the host myocar-
dial fibers. This observation suggests a potential for produc-
tive synchronous contraction, or structural enhancement,
both of which could contribute to improvements in systolic
or diastolic function or ameliorate remodeling. However,
the potential for synchronous contraction would need to be
confirmed by investigating for gap junction formation with
immunostaining with anti-connexin 43 antibodies and
through investigation with electron microscopy (20,31). In
the absence of these data, statements regarding the pro-
posed mechanism by which skeletal muscle implants may
offer improvement in myocardial function are significantly
limited.
Areas of myoblast engraftment demonstrated healthy
graft morphology even though the cells were located in
some cases in a large area containing a mature scar. Further,
there was a significant increase in the number of blood
vessels associated with the graft sites documented in one
patient. New vessels were formed in the area of the grafts,
and such vasculogenesis may be necessary for long-term
survival of the transplanted cells. Whether this observed
increase in vasculogenesis is a consequence of myoblast
engraftment or localized trauma from needle site injections
is unknown at this time. Alternatively, myoblast survival and
differentiation may have occurred only in those areas of
infarct that had pre-existing improvements in microvessel
formation. Additionally, these data demonstrate that simul-
taneous revascularization with coronary artery bypass graft-
ing or percutaneous revascularization with stent or angio-
plasty is not a requirement for successful graft survival.
Equally important to the observed increase in vessel
formation was the lack of an ongoing immune reaction to
skeletal myoblast transplant. Cells were cultured in the
presence of foreign proteins during the expansion of the
cells that could act as a stimulus for an immune response.
Figure 6. Trichrome staining of a graft site demonstrating the presence of giant cells. A and B show an area adjacent to the grafted cells where giant cells
have formed. The boxed area in A is shown at higher magnification in B. Multinucleated giant cells are associated with refractile material (arrows), probably
plastic that was introduced with the cells. Note that the area of engrafted cells is free from any giant cells.
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However, we saw no evidence of an immune response.
Multinucleated giant cells within areas of the transplants
were present in only a few of the sections examined. These
cells were always associated with refractile, non-cellular
material that may have been introduced at the time of the
cell injection.
Quantitation of the number of total cells surviving trans-
plant is difficult to calculate accurately. We found surviving
cells associated with all identified needle tracts. Moreover,
not all cells are successfully delivered to the myocardium.
We did note leakage of cells from the myocardium after
injection of myoblasts into the heart. In particular, in
Patient 3 we found large numbers of surviving myotubes
associated with epicardial fat, evidence that cells had leaked
back from the injection site. Thus, because we cannot
determine the actual number of cells successfully injected,
our assumptions on cell survival are based on the 100%
delivery of cells. Ultimately, the efficiency of engraftment
will have to wait for results from continuing patient studies.
Further, efforts are under way to determine the most
effective method of cell delivery to the myocardium, and
likely significant gains in efficiency will be made through
those studies.
One of the limitations of this study was the absence of
functional data. We specifically designed the experimental
protocol not to look for efficacy of cellular transplants. This
does not rule out that some degree of improvement from
skeletal muscle transplant may have occurred, but rather we
did not specifically investigate for it. One of the most
accurate methods for determining functional improvement
in regional myocardial segments, magnetic resonance imag-
ing, was not feasible in this patient population owing to the
presence of the LVAD. Thus, because of this limitation, the
relatively low number of cell transplants, and the small area
injected (3 cm by 3 cm), we chose not to design our protocol
to look for functional improvement using less sensitive
indicators of regional myocardial function.
Cell transplants are rapidly advancing as a potential new
Figure 7. Representative CD-31 staining of a graft site. An antibody to human CD-31 was used to stain graft sections. A shows a representative micrograph
in the area of the graft. The dotted line demarcates the border area between the transplant and the adjacent scar. Note the enhanced area of CD-31 staining
within the engrafted section. B shows the results from quantitative counts to compare the number of CD-31 vessels at the graft (white bar) and in the
adjacent scar (gray bar). Scale bar  100 m.
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therapy. Our data demonstrate the feasibility of myoblast
cell transplantation as a potential treatment for cardiac
disease. Further studies are warranted in this new area of
medical therapy, in particular to correlate cell survival with
clinical improvement in cardiac function. This study clearly
verifies that survival and differentiation patterns observed in
animals can also be obtained in human patients with chronic
ischemic cardiac damage.
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